Search results
Results from the WOW.Com Content Network
More severe symptoms include fever, seizures, irregular heartbeat, delirium, and coma. [75] [76] [11] If signs or symptoms arise, discontinue treatment with serotonergic agents immediately. [75] It is recommended to washout 4 to 5 half-lives of the serotonergic agent before using an MAO inhibitor. [77]
This is a list of major and frequently observed neurological disorders (e.g., Alzheimer's disease), symptoms (e.g., back pain), signs (e.g., aphasia) and syndromes (e.g., Aicardi syndrome). There is disagreement over the definitions and criteria used to delineate various disorders and whether some of these conditions should be classified as ...
Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. [6] [9] It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. [9]
Sympathomimetic drugs can increase motivation, cognition, motor performance and alertness in persons with encephalopathy caused by brain injury, chronic infections, strokes, brain tumors. [ 10 ] When the encephalopathy is caused by untreated celiac disease or non-celiac gluten sensitivity , the gluten-free diet stops the progression of brain ...
Preclinical and clinical research indicates that drugs inhibiting the reuptake of all three of these neurotransmitters can produce a more rapid onset of action and greater efficacy than traditional antidepressants. [8] DA may promote neurotrophic processes in the adult hippocampus, as 5-HT and NA do.
The review authors noted that research into the potential brain benefits of GLP-1 medications needs more research but are optimistic about the future of these drugs in how they may boost brain health.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
A link between these types of drugs and cognitive impairment isn't a totally new discovery, but for the first time, researchers used brain imaging techniques to determine the physical changes ...